Nightstar Therapeutics plc, a clinical-stage gene therapy company, focuses on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases in the United Kingdom. The company's lead product candidate is NSR-REP1, a candidate that is in phase 3 clinical development for the treatment of patients with choroideremia. It is also developing NSR-RPGR, a candidate that is in Phase 1/2 clinical trials for the treatment of patients with X-linked retinitis pigmentosa, an inherited X-linked recessive retinal disease; and NSR-BEST1, a candidate that is in preclinical development stage for the treatment of best vitelliform macular dystrophy. In addition, the company is developing NSR-ABCA4, a candidate that is in preclinical development stage for the treatment of Stargardt disease. The company was founded in 2013 and is headquartered in London, the United Kingdom.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone44-20-7611-2077
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees27
Next Earnings Date4/2/2019 (Estimated)
OptionableNot Optionable
Nightstar Therapeutics (NASDAQ:NITE) Frequently Asked Questions
What is Nightstar Therapeutics' stock symbol?
Nightstar Therapeutics trades on the NASDAQ under the ticker symbol "NITE."
How were Nightstar Therapeutics' earnings last quarter?
Nightstar Therapeutics PLC (NASDAQ:NITE) posted its earnings results on Tuesday, November, 13th. The company reported ($0.27) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.40) by $0.13. View Nightstar Therapeutics' Earnings History.
When is Nightstar Therapeutics' next earnings date?
What price target have analysts set for NITE?
10 Wall Street analysts have issued twelve-month price objectives for Nightstar Therapeutics' shares. Their forecasts range from $25.18 to $40.00. On average, they expect Nightstar Therapeutics' share price to reach $28.5680 in the next year. This suggests a possible upside of 13.0% from the stock's current price. View Analyst Price Targets for Nightstar Therapeutics.
What is the consensus analysts' recommendation for Nightstar Therapeutics?
10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nightstar Therapeutics in the last year. There are currently 7 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Nightstar Therapeutics.
What are Wall Street analysts saying about Nightstar Therapeutics stock?
Here are some recent quotes from research analysts about Nightstar Therapeutics stock:
- 1. Cantor Fitzgerald analysts commented, ": We are reiterating our Overweight rating and $42/share price target on Nightstar Therapeutics. This morning, Spark (N) announced a definitive agreement to be acquired by Roche (RHHBY, NC) for $4.8 billion, or $114.50/share (a 122% premium). While we believe the primary driver of the acquisition was Spark’s hemophilia A program, we have observed a trend in late- stage gene therapy company acquisitions. Given that Nightstar is one of the furthest along with a Phase 3 trial reading out next year, we believe the company deserves a seat at the table for acquisition talks and interest from pharma." (2/26/2019)
- 2. According to Zacks Investment Research, "Nightstar Therapeutics Limited is a clinical-stage gene therapy company. It focused on developing and commercializing novel one-time treatments for patients suffering from rare inherited retinal diseases including choroideremia, X-linked retinitis pigmentosa and Best vitelliform macular dystrophy. The company operates primarily in North America and Europe. Nightstar Therapeutics Limited is based in LONDON, United Kingdom. " (1/9/2019)
- 3. Mizuho analysts commented, "We attended Nightstar’s R&D Day yesterday where management presented preliminary data from the dose escalation study of NSR-RPGR for the treatment of X-Linked Retinitis Pigmentosa. We were encouraged by early signals observed in all cohort 3 patients and 2/6 patients in cohorts 4 and 5. However, the therapeutic dose to be taken into the upcoming expansion study remains to be determined as higher dose responders required a second course of steroids to control mild sub-retinal inflammation. The next important catalyst for the shares will be 2Q19 with six-months follow-up data from the dose escalation study. We maintain our Buy rating on the stock." (9/25/2018)
Has Nightstar Therapeutics been receiving favorable news coverage?
Media stories about NITE stock have trended positive this week, InfoTrie reports. InfoTrie identifies positive and negative press coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Nightstar Therapeutics earned a media sentiment score of 2.1 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the company's share price in the immediate future.
Who are some of Nightstar Therapeutics' key competitors?
Some companies that are related to Nightstar Therapeutics include Repligen (RGEN), Acceleron Pharma (XLRN), Halozyme Therapeutics (HALO), Aerie Pharmaceuticals (AERI), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Denali Therapeutics (DNLI), Atara Biotherapeutics (ATRA), Audentes Therapeutics (BOLD), Orchard Therapeutics (ORTX), Rubius Therapeutics (RUBY), Momenta Pharmaceuticals (MNTA), Alector (ALEC), Iovance Biotherapeutics (IOVA) and Editas Medicine (EDIT).
What other stocks do shareholders of Nightstar Therapeutics own?
Who are Nightstar Therapeutics' key executives?
Nightstar Therapeutics' management team includes the folowing people:
- Mr. David Fellows, CEO & Director (Age 62)
- Mr. Senthil Vel Sundaram, Chief Financial Officer (Age 41)
- Dr. Gregory Scott Robinson, Chief Scientific Officer (Age 60)
- Brian Luque, Sr. Mang. of Investor Relations
- Mr. Seokho Bryan Yoon Esq., Gen. Counsel & Sec. (Age 40)
When did Nightstar Therapeutics IPO?
(NITE) raised $76 million in an initial public offering on Thursday, September 28th 2017. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Jefferies, Leerink Partners and BMO Capital Markets acted as the underwriters for the IPO and Wedbush PacGrow and Chardan were co-managers.
Who are Nightstar Therapeutics' major shareholders?
Nightstar Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Sectoral Asset Management Inc (0.83%), Tekla Capital Management LLC (0.35%), United Services Automobile Association (0.22%), Squarepoint Ops LLC (0.16%), Millennium Management LLC (0.13%) and Virtus ETF Advisers LLC (0.10%). Company insiders that own Nightstar Therapeutics stock include David A Fellows, Gregory Scott Robinson and Senthil Vel Sundaram. View Institutional Ownership Trends for Nightstar Therapeutics.
Which major investors are selling Nightstar Therapeutics stock?
NITE stock was sold by a variety of institutional investors in the last quarter, including Millennium Management LLC, Tekla Capital Management LLC, United Services Automobile Association and Sectoral Asset Management Inc. Company insiders that have sold Nightstar Therapeutics company stock in the last year include David A Fellows, Gregory Scott Robinson and Senthil Vel Sundaram. View Insider Buying and Selling for Nightstar Therapeutics.
Which major investors are buying Nightstar Therapeutics stock?
How do I buy shares of Nightstar Therapeutics?
Shares of NITE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nightstar Therapeutics' stock price today?
One share of NITE stock can currently be purchased for approximately $25.29.
How big of a company is Nightstar Therapeutics?
Nightstar Therapeutics has a market capitalization of $710.65 million. The company earns $-29,680,000.00 in net income (profit) each year or ($1.63) on an earnings per share basis. Nightstar Therapeutics employs 27 workers across the globe.
What is Nightstar Therapeutics' official website?
How can I contact Nightstar Therapeutics?
Nightstar Therapeutics' mailing address is 215 EUSTON ROAD, LONDON X0, NW1 2BE. The company can be reached via phone at 44-20-7611-2077 or via email at [email protected]
MarketBeat Community Rating for Nightstar Therapeutics (NASDAQ NITE)
MarketBeat's community ratings are surveys of what our community members think about Nightstar Therapeutics and other stocks. Vote "Outperform" if you believe NITE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NITE will underperform the S&P 500 over the long term. You may vote once every thirty days.
